Total Sales Volume (FY26)
42,389 MT
+6.5% YoY
Volume growth contributed ~6.5% to revenue growth; balance from price/mix.
PRIVISPECIALITYCHEMICALS
Manufacturing
15 May 2026
Privi Speciality Chemicals Ltd — Q4 FY26
Privi Speciality Chemicals delivered a strong Q4 FY26 with revenue of ₹725.7 Cr (+15.3% YoY) and EBITDA of ₹184.4 Cr (+25.1% YoY), driven by volume growth, price increases, and improved product mix.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Privi Speciality Chemicals delivered a strong Q4 FY26 with revenue of ₹725.7 Cr (+15.3% YoY) and EBITDA of ₹184.4 Cr (+25.1% YoY), driven by volume growth, price increases, and improved product mix. EBITDA margin expanded to 25.4% (+200 bps YoY) due to cost optimization and operational efficiencies. PAT surged 50.5% to ₹95.7 Cr. For FY26, revenue grew 21.7% to ₹2,582.9 Cr, with EBITDA margin of 25.8%. Management guided for ~20% revenue growth in FY27 with sustained 25%+ EBITDA margins, supported by capacity expansion to 54,000 MT by June 2026 and new specialty products (maltol, cyclopentanone) commercializing by Q1 FY27. The JV with Privi turned profitable in Q4. Key risk: raw material price volatility and supply chain disruptions from geopolitical tensions could pressure margins.
Key Numbers
Net Debt to EBITDA
1.33x
flat
Net debt stood at ₹876 Cr; ratio reflects healthy leverage.
Working Capital Cycle
117 days
-3 days YoY
Improved working capital management; expected to remain near current levels.
ROE / ROCE (FY26)
22.05% / 22.42%
+420 bps / +450 bps YoY
Strong profitability drove returns above 20% threshold.
Management Guidance
Revenue growth of ~20% in FY27
Management expects ~20% revenue growth on standalone basis for FY27, driven by volume and new capacities.
Management guidance revenueEBITDA margin to sustain above 25%
Management guided for 25%+ EBITDA margins going forward, supported by operational efficiencies and product mix.
Management guidance marginsPhase 1 capacity expansion to 54,000 MT by June 2026
First phase of capex to increase total installed capacity to 54,000 MT per annum by June 2026.
Management guidance capexNew specialty products (maltol, cyclopentanone) commercial by Q1 FY27
Maltol, ethyl maltol, and cyclopentanone projects to achieve mechanical completion by June 2026, with commercial production soon after.
Management guidance growthKey Risks
Raw material price volatility and supply chain disruptions
Geopolitical tensions (West Asia) could increase freight costs and delay raw material shipments, impacting margins.
high · analyst_questionGross margin sequential dip due to contract overlap
Q4 gross margin declined sequentially due to annual contract overlap; management says to judge on annual basis.
medium · analyst_questionBiotechnology demonstration plant capex risk
Capex of ₹70-75 Cr for demo plant may not yield commercial returns if technology fails to scale economically.
medium · management_commentaryCustomer concentration in JV with Jodan
JV with Jodan is exclusive for certain high-end chemicals; any disruption could impact JV profitability.
low · data_observationNotable Quotes
We are confident that we'll be able to pass on the price increase and we because you see I would I would yet tell you I'm not saying I'm the most competitive but I am definitely in the lead and people do have confidence by paying one or two% higher.
We are indeed China plus one you know so so on on a lighter note because we are backward integrated we are definitely China plus plus one.
Our expectation is to reach beyond the expectations one can imagine.
Frequently Asked Questions
What was Privi Speciality Chemicals's revenue in Q4 FY26?
Privi Speciality Chemicals reported revenue of ₹726 Cr in Q4 FY26, representing a +15.29% change compared to the same quarter last year.
What guidance did Privi Speciality Chemicals management give for FY27?
Revenue growth of ~20% in FY27: Management expects ~20% revenue growth on standalone basis for FY27, driven by volume and new capacities. EBITDA margin to sustain above 25%: Management guided for 25%+ EBITDA margins going forward, supported by operational efficiencies and product mix. Phase 1 capacity expansion to 54,000 MT by June 2026: First phase of capex to increase total installed capacity to 54,000 MT per annum by June 2026. New specialty products (maltol, cyclopentanone) commercial by Q1 FY27: Maltol, ethyl maltol, and cyclopentanone projects to achieve mechanical completion by June 2026, with commercial production soon after.
What are the key risks for Privi Speciality Chemicals in FY27?
Key risks include Raw material price volatility and supply chain disruptions — Geopolitical tensions (West Asia) could increase freight costs and delay raw material shipments, impacting margins.; Gross margin sequential dip due to contract overlap — Q4 gross margin declined sequentially due to annual contract overlap; management says to judge on annual basis.; Biotechnology demonstration plant capex risk — Capex of ₹70-75 Cr for demo plant may not yield commercial returns if technology fails to scale economically.; Customer concentration in JV with Jodan — JV with Jodan is exclusive for certain high-end chemicals; any disruption could impact JV profitability..
Did Privi Speciality Chemicals meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Privi Speciality Chemicals Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.